Status:
COMPLETED
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
Lead Sponsor:
Pfizer
Collaborating Sponsors:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to t...
Eligibility Criteria
Inclusion
- Diagnosis of mild to moderate Alzheimer's Disease
- Mini Mental Status Exam (MMSE) of 16-26
Exclusion
- Significant Neurological Disease
- Major Psychiatric Disorder
- Clinically significant systemic illness
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00752232
Start Date
December 1 2008
End Date
July 1 2012
Last Update
January 1 2016
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Suwa Red Cross Hospital
Suwa, Nagano, Japan, 392-8510
2
Tazuke Kofukai Medical Research Institute Kitano Hospital
Osaka, Osaka, Japan, 530-8480
3
Osaka Medical College Hospital
Takatsuki, Osaka, Japan, 569-8686
4
Meitetsu Hospital
Aichi, Japan, 451-8511